Effectiveness of low-dose intradermally administered hepatitis B virus vaccine

ABSTRACT

Hepatitis B vaccine is underutilized due to high cost. A study was performed to see the effectiveness of yeast derived recombinant vaccine in low dose [0.1 ml; 2 micro g] given at 0, 1,2 and 6 months in 50 seronegative individuals. Out of them 39 subjects [78%] developed anti-hepatitis B surface antigen [anti HBs] in a concentration greater than 10 IU/L which is considered to be protective. None of them had any significant side effect except for minor local soreness at the site of injection